The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases
The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases -A Multi-center, Prospective, Interventional Study (PRECEDE)
AstraZeneca
3,000 participants
Nov 28, 2025
INTERVENTIONAL
Conditions
Summary
This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) subjects , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).
Eligibility
Inclusion Criteria8
- Give signed written informed consent to participate.
- At least 40 years of age at baseline visit.
- Previous or newly diagnosed by at least one of the 3 types of CVD which are,
- Coronary heart disease ( CHD )
- Atrial fibrillation (AF )
- Chronic heart failure ( CHF )
- Subjects have no absolute contraindications to spirometry testing.
- Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators.
Exclusion Criteria4
- Significant diseases or conditions, which, in the opinion of the investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
- Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.
- Subjects who are not able to provide written informed consent.
- Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.
Interventions
The intervention is implemented at the investigator level and the patient level, consisted of 3 parts： 1. Disease education * Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled. * Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study. 2. Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD. 3. Follow-up management:the subjects will be followed up every 4 weeks.
Locations(69)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06909773